Skip to content
AnalystLens

BIOGEN INC. 8-K Report, Financial Results (Jul 1, 2026)

Reports
Earnings & Results
Filing Date
Filed July 1, 2026
Period End
July 1, 2026
Security
BIIB
In the record · 2016–202610-K1110-Q328-K112

BIIB filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 112 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Feb ’17Feb ’17
  2. Material agreement8-K · Feb ’20Feb ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Jan ’25Jan ’25

01—Abstract

Summary

Summary of the 8-K filed July 1, 2026. Cited figures are marked; the original filing is the authoritative source.

Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026.

The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 milliona pre-tax, translating to an impact of roughly $0.95 per diluted share.

Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 millionb and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.

02—Key points

Key Highlights

  1. Biogen expects acquired IPR&D, upfront, and milestone expenses to impact Q2 2026 results.
  2. Estimated pre-tax charge for Q2 2026 IPR&D is approximately $164 million.
  3. Q2 2026 IPR&D expense is projected to reduce GAAP and non-GAAP EPS by approximately $0.95.
  4. Biogen anticipates a higher range of IPR&D expenses for Q3 2026, between $290 million and $320 million.
  5. The projected Q3 2026 IPR&D expense is expected to impact GAAP and non-GAAP EPS by $1.75 to $1.95.
  6. These expenses relate to collaborations, license agreements, and potential milestones/transactions.
  7. The disclosed figures are preliminary estimates and subject to change pending final financial closing procedures.

03—Questions

Frequently Asked Questions

  1. What is the main reason for the expected impact on Biogen's Q2 and Q3 2026 earnings?

    The primary reason for the expected impact on Biogen's earnings is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaboration and license agreements. These costs are associated with potential future milestones and transactions that have not yet closed.

  2. How much will the Q2 2026 IPR&D expenses affect earnings per share?

    Biogen anticipates that the acquired IPR&D, upfront, and milestone expenses for the second quarter of 2026 will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.95.

  3. What is the estimated financial impact for the third quarter of 2026?

    For the third quarter of 2026, Biogen expects acquired IPR&D, upfront, and milestone expenses to range from approximately $290 million to $320 million. This is projected to impact GAAP and non-GAAP net income per diluted share by approximately $1.75 to $1.95.

  4. Are these financial figures final?

    No, the figures provided are preliminary, unaudited estimates. The results for the quarter ended June 30, 2026, have not been finalized and are subject to Biogen's financial statement closing procedures. There is no assurance that the final reported results will not differ from these estimates.

04—Continue

← View all 8-K filings